Global Thrombin Market is anticipated to grow at a higher CAGR in the forthcoming period. Thrombin is an allosteric enzyme that occurs in dual forms, slow and fast that vary extensively regarding their specificities pertaining to synthetic and natural amide substances. Both the forms importantly account for in vivo state and the allosteric stability can be disturbed by combining effectors and natural substrates.
Since the fast form can cleave with fibrinogen with higher specificity due it procoagulant nature. The slow form cleaves with protein C at a higher specificity due it anticoagulant nature. From the commercial point, thrombin is a particular enzyme called serine protease, synthesized from a predecessor glycoprotein named prothrombin. Thrombin is produced naturally in the body and also available in an artificial form. Artificially prepared thrombin possesses the ability to convert fibrinogen into fibrin which helps in formation of thrombus upon the injury site.
Driving factors responsible for the growth of thrombin market includes rise in cases of severe complications, bleeding due to major injuries and rising prevalence of hemostasis. Based on segmentation by product, the market includes bovine thrombin, recombinant thrombin and human thrombin. Human thrombin is further sub-segmented into alpha, beta gamma thrombin. Based on segmentation by dosage, the thrombin market includes powder form, pad from, spray kits and solution form. Segmentation on the basis of end-user for thrombin industry includes hospitals, diagnostics and clinics, academic and research institutes.
Geographically, thrombin market spans North America, Latin America, Europe, Asia-Pacific, Middle-East and Africa. North America is anticipated to lead the global market growth owing to higher cases of surgeries and better medical infrastructure. APAC and Europe market is expected to gain a higher CAGR growth owing to rise in population and better medical infrastructure. MEA regions are also expected to gain a moderate CAGR in the forthcoming period owing to rise in cases of homeostasis and growing medical infrastructure. The key players in the thrombin market include Bayer, CSL, Baxter, CSL, Grifols, GE Healthcare, Hualan Biological, Haematologic Technologies Inc, Pfizer, Octapharma, Shanghai RAAS and Omrix Biopharmaceuticals Ltd.
Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Thrombin in these regions, from 2012 to 2022 (forecast), covering
• North America
• Southeast Asia
Global Thrombin market competition by top manufacturers, with production, price, revenue (value) and market share for each manufacturer; the top players including
• GE Healthcare
• Hualan Biological
• Haematologic Technologies Inc.
• Omrix Biopharmaceuticals Ltd.
• Shanghai RAAS
On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
• Powder Form
• Solution Form
• Pad Form
• Spray Kits
On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate of Thrombin for each application, including
• Diagnostics & Clinics
• Academic and Research Institutes
Research Support Specialist, USA